A community trial of the impact of improved sexually transmitted disease treatment on the HIV epidemic in rural Tanzania: 2. Baseline survey results. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


A community trial of the impact of improved sexually transmitted disease treatment on the HIV epidemic in rural Tanzania: 2. Baseline survey results.

AIDS. 1995 Aug;9(8):927-34. Unique Identifier : AIDSLINE MED/96014968
Grosskurth H; Mosha F; Todd J; Senkoro K; Newell J; Klokke A; Changalucha J; West B; Mayaud P; Gavyole A; et al; African Medical and Research Foundation, Mwanza, Tanzania.


Abstract: OBJECTIVES: To determine baseline HIV prevalence in a trial of improved sexually transmitted disease (STD) treatment, and to investigate risk factors for HIV. To assess comparability of intervention and comparison communities with respect to HIV/STD prevalence and risk factors. To assess adequacy of sample size. SETTING: Twelve communities in Mwanza Region, Tanzania: one matched pair of roadside communities, four pairs of rural communities, and one pair of island communities. One community from each pair was randomly allocated to receive the STD intervention following the baseline survey. METHODS: Approximately 1000 adults aged 15-54 years were randomly sampled from each community. Subjects were interviewed, and HIV and syphilis serology performed. Men with a positive leucocyte esterase dipstick test on urine, or reporting a current STD, were tested for urethral infections. RESULTS: A total of 12,534 adults were enrolled. Baseline HIV prevalences were 7.7% (roadside), 3.8% (rural) and 1.8% (islands). Associations were observed with marital status, injections, education, travel, history of STD and syphilis serology. Prevalence was higher in circumcised men, but not significantly after adjusting for confounders. Intervention and comparison communities were similar in the prevalence of HIV (3.8 versus 4.4%), active syphilis (8.7 versus 8.2%), and most recorded risk factors. Within-pair variability in HIV prevalence was close to the value assumed for sample size calculations. CONCLUSIONS: The trial cohort was successfully established. Comparability of intervention and comparison communities at baseline was confirmed for most factors. Matching appears to have achieved a trial of adequate sample size. The apparent lack of a protective effect of male circumcision contrasts with other studies in Africa.
Keywords: Adolescence Adult Analysis of Variance Circumcision Cohort Studies Community Health Services Female Human HIV Infections/COMPLICATIONS/*EPIDEMIOLOGY/*PREVENTION & CONTROL Male Middle Age Risk Factors Rural Population Sexually Transmitted Diseases/COMPLICATIONS/*THERAPY Support, Non-U.S. Gov't Syphilis/COMPLICATIONS/EPIDEMIOLOGY/THERAPY Tanzania/EPIDEMIOLOGY CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIALKWDadolescenceadultanalysisofvariancecircumcisioncohortstudiescommunityhealthservicesfemalehumanhivinfections/complications/KWDepidemiology/KWDprevention&controlmalemiddleageriskfactorsruralpopulationsexuallytransmitteddiseases/complications/KWDtherapysupport,non-uKWDsKWDgov'tsyphilis/complications/epidemiology/therapytanzania/epidemiologyclinicaltrialjournalarticlerandomizedcontrolledtrial
960228
M9621061

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .